Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension Results From Randomized Controlled Pilot Studies by Voswinckel, Robert et al.
F
T
R
R
A
T
F
G
N
s
i
e
s
s
C
P
h
G
S
r
R
a
M
s
s
A
L
g
n
p
S
p
a
Journal of the American College of Cardiology Vol. 48, No. 8, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
PPulmonary Vascular Disease
avorable Effects of Inhaled
reprostinil in Severe Pulmonary Hypertension
esults From Randomized Controlled Pilot Studies
obert Voswinckel, MD,* Beate Enke, MD,* Frank Reichenberger, MD,* Markus Kohstall, MD,*
ndree Kreckel, MD,* Stefanie Krick, MD,* Henning Gall, MD,* Tobias Gessler, MD, PHD,*
homas Schmehl, PHD,* Hossein A. Ghofrani, MD,* Ralph Theo Schermuly, PHD,*
riedrich Grimminger, MD, PHD,* Lewis J. Rubin, MD,† Werner Seeger, MD,* Horst Olschewski, MD*‡
iessen, Germany; La Jolla, California; and Graz, Austria
OBJECTIVES This study sought to investigate the effects of inhaled treprostinil on pulmonary hemody-
namics and gas exchange in severe pulmonary hypertension.
BACKGROUND Inhaled iloprost therapy has a proven clinical efficacy in pulmonary arterial hypertension, but
this therapy necessitates 6 to 9 inhalation sessions per day. Treprostinil has a longer plasma
half-life and might provide favorable properties when applied by inhalation.
METHODS Three different studies were conducted on a total of 123 patients by means of right heart
catheterization: 1) a randomized crossover-design study (44 patients), 2) a dose escalation
study (31 patients), and 3) a study of reduction of inhalation time while keeping the dose fixed
(48 patients). The primary end point was the change in pulmonary vascular resistance (PVR).
RESULTS The mean pulmonary arterial pressure of the enrolled patients was approximately 50 mm Hg
in all studies. In study 1, both treprostinil and iloprost at an inhaled dose of 7.5 g displayed
a comparable PVR decrease, with a significantly different time course (p 0.001), treprostinil
showing a more sustained effect on PVR (p  0.0001) and fewer systemic side effects. In
study 2, effects of inhalation were observed for 3 h. A near-maximal acute PVR decrease was
observed at 30 g treprostinil. In study 3, treprostinil was inhaled at increasing concentrations
with a pulsed ultrasonic nebulizer, mimicking a metered dose inhaler. A dose of 15 g
treprostinil was inhaled with 18, 9, 3, 2 pulses, or 1 pulse, each mode achieving comparable,
sustained pulmonary vasodilation without significant side effects.
CONCLUSIONS Inhaled treprostinil exerts sustained pulmonary vasodilation with excellent tolerability at
relatively low doses and may be inhaled in a few breaths. (J Am Coll Cardiol 2006;48:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.0621672–81) © 2006 by the American College of Cardiology Foundation
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hown clinical efficacy, but there remains a need for further
mprovement (1). Continuous intravenous infusion of
poprostenol improves hemodynamics, quality of life, and
urvival. The stable prostacyclin analog treprostinil might
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ccepted June 13, 2006.ave comparable clinical effects (2–4), but intravenous
herapy is prone to catheter-related infections, drug toler-
nce, and major systemic side effects. The inhalation of
loprost is clinically efficacious in patients with severe
ulmonary arterial hypertension (5) and was recently ap-
roved for use in Europe, Australia, and the U.S. However,
to 9 iloprost inhalation sessions daily with 6- to 12-min
nhalation times are recommended, consuming considerable
ime every day.
The stable prostacyclin analog treprostinil has been
pproved in the U.S., Israel, Australia, and Canada for
reatment of pulmonary arterial hypertension (New York
eart Association functional class II to IV) and by the
uropean Medical Agency for idiopathic PAH (New
ork Heart Association functional class III) via contin-
ous subcutaneous infusion (6) and continuous intrave-
ous infusion (4). Subcutaneous application circumvents
eptic events caused by catheter infections related to
ntravenous infusion; however, local pain and tissue
eaction at the infusion site may limit effective dosing and
ong-term treatment. Treprostinil possesses a longer
lasma half-life than iloprost (7) and may show alterna-
ive tissue binding characteristics that could result in
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October 17, 2006:1672–81 Inhaled Treprostinil in Pulmonary Hypertensionavorable pharmacodynamic features when delivered via
he inhaled route. A recent case report suggests that
nhaled treprostinil might be tolerable and efficacious in
he long term (8).
We asked whether inhaled treprostinil had acute pul-
onary vasodilative properties and whether it might be
uperior to inhaled iloprost in terms of duration of effect
nd systemic side effects. We then increased both the
otal inhaled dose to define a threshold for systemic side
ffects, and the drug concentration to reduce the inhala-
ion time.
ETHODS AND PATIENTS
ll studies were approved by the institutional ethics com-
ittee of the University of Giessen, and written informed
onsent was obtained from all 123 enrolled patients. All
nhalations were performed with the Optineb ultrasonic
ebulizer (Nebutec, Elsenfeld, Germany).
Study 1 was a randomized, open-label, single-blind
rossover study. The primary objective was to compare the
cute hemodynamic effects and the systemic side effects of
nhaled treprostinil with inhaled iloprost at comparable
oses. A total number of 44 patients with moderate to
evere precapillary pulmonary hypertension were enrolled.
atient characteristics and hemodynamic as well as gas
xchange parameters are outlined in Table 1.
Each patient underwent right heart catheterization and
nhaled both iloprost and treprostinil on the same day
uring hemodynamic monitoring. The drugs were admin-
stered consecutively with a 1-h interval between the drug
dministrations. One-half of the study patients initially
nhaled treprostinil and then inhaled iloprost (n  22), and
he other half initially inhaled iloprost and then inhaled
reprostinil (n  22). Patients were randomized to 1 of the
groups and blinded regarding the sequence of the study
rugs. Drug effects were monitored for 60 min after each
nhalation session. Iloprost was inhaled at a concentration of
g/ml (6 min inhalation time; n  44) and treprostinil
as inhaled at concentrations of 4 g/ml (6 min inhalation;
 14), 8 g/ml (6 min inhalation; n  14) or 16 g/ml
3 min inhalation; n  16). Based on previous biophysical
haracterization of the ultrasonic device with iloprost and
reprostinil solution, this corresponds to total inhaled doses
f 7.5 g iloprost and treprostinil (4 g/ml) and 15 g
reprostinil (8 g/ml and 16 g/ml), respectively.
Study 2 was a randomized, open-label, single-blind,
Abbreviations and Acronyms
PVR  pulmonary vascular resistance
AUC  area under the curve
ABC  areas between curves
PAP  pulmonary arterial pressure
SAP  systemic arterial pressurelacebo-controlled study. The primary objectives were to Ta
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Inhaled Treprostinil in Pulmonary Hypertension October 17, 2006:1672–81escribe the pharmacodynamic and pharmacokinetic effects
f inhaled treprostinil at a well-tolerated dose (30 g) and
o explore the highest tolerated single dose. A total number
f 31 patients inhaled either placebo or treprostinil; each
atient underwent 1 inhalation session. The first 16 patients
ere randomized to 30 g treprostinil (16 g/ml, n  8)
r placebo (stock solution containing the same buffer and
reservative concentrations as treprostinil 16 g/ml).
ubsequent patients received 60 g treprostinil (32
g/ml; n  6), 90 g treprostinil (48 g/ml; n  6) and
20 g treprostinil (64 g/ml; n  3). Inhalation time
as 6 min for all groups. Hemodynamics, gas exchange,
nd arterial treprostinil concentrations were recorded for
80 min.
Study 3 was a randomized, open-label, single-blind study.
he primary objective was to explore the shortest possible
nhalation time for a 15-g dose of inhaled treprostinil. A
otal of 48 patients inhaled 1 dose of treprostinil during
emodynamic monitoring. The drug was applied in 18, 9, 3,
or 1 breaths. The aerosol was generated by a pulsed
ltrasonic nebulizer (Ventaneb; Nebutec, Elsenfeld, Ger-
any) in cycles consisting of 2-s aerosol production (pulse)
nd a 4-s pause. The device included an optic-acoustical
rigger enabling the patient to synchronize the inspiration to
he end of the aerosol pulse, thereby providing exact dosage.
he treprostinil dose of 15 g was either generated during
8 cycles (Optineb filled with 100 g/ml treprostinil, n 
), 9 cycles (200 g/ml treprostinil, n  6), 3 cycles (600
g/ml treprostinil, n  21), 2 cycles (1,000 g/ml trepro-
tinil, n  7), or 1 cycle (2,000 g/ml treprostinil, n  8).
emodynamics and gas exchange were recorded for 120 to
80 min.
Treprostinil plasma concentrations were assessed in study
at 10, 15, 30, 60, and 120 min after inhalation. Trepro-
tinil quantification was performed by Alta Analytical Lab-
ratory (El Dorado Hills, California) with a validated liquid
hromatography atmospheric-pressure ionization tandem
igure 1. Response of pulmonary vascular resistance (PVR) to inhaled trepr
n  22) versus first inhalation session with iloprost (n  22). (B) Second
ith iloprost (n  22). The PVR decrease with treprostinil was delayed anhe first period, in the second period, the effects of both drugs appeared shortene
nterval).ass spectrometry as previously described (9). Mixed ve-
ous blood was drawn at 10, 15, 30, 60, 120, and 240 min
fter inhalation, centrifuged, and the plasma frozen at
80°C until temperature-controlled shipping on dry ice.
tatistics. For statistical analysis of study 1, the repeated
ulmonary vascular resistance (PVR) measurements after
nhaled iloprost and treprostinil were subjected to a
-factorial analysis of variance (factors: time [A], drug [B],
reprostinil concentration [C]) to avoid multiple testing.
he time to maximum PVR decrease after inhalation of
loprost versus treprostinil was compared by paired t test.
he area under the curve (AUC) was calculated from the
tart of inhalation until 60 min after inhalation. Means,
tandard error of the mean, and 95% confidence intervals
ere calculated. For studies 2 and 3, areas between curves
ABC) were calculated between placebo inhalation (study
) and the respective treprostinil inhalation until 180 min
study 2) and 120 min (study 3) after the end of
nhalation.
ESULTS
he inhalation of both iloprost and treprostinil in study 1
esulted in a rapid decrease in PVR and pulmonary arterial
ressure (PAP) (Figs. 1 to 3). No significant differences
ere observed for the AUC of PVR decrease after inhala-
ion of 7.5 g treprostinil in 6 min (AUC 12.6  7.0%),
5 g treprostinil in 6 min (AUC 13.3  3.2%), and 15
g treprostinil in 3 min (AUC 13.6  4.3%). The AUC
or PVR after the inhalation of 7.5 g iloprost in 6 min was
7.7  3.7% (mean  95% confidence interval). An
verview of the pooled data of treprostinil inhalation com-
ared with iloprost inhalation is given in Figure 3. The
aximum effects of iloprost and treprostinil on PVR were
omparable, but this effect was reached significantly later
fter treprostinil inhalation (18  2 min) compared with
loprost (8  1 min; mean  SEM, p  0.0001) and lasted
l versus iloprost: period effects. (A) First inhalation session with treprostinil
lation session with treprostinil (n  22) versus second inhalation session
longed compared with that for iloprost. Because of carryover effects fromostini
inha
d pro
d. Data are shown as percent of baseline values (mean  95% confidence
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October 17, 2006:1672–81 Inhaled Treprostinil in Pulmonary Hypertensiononsiderably longer (after 60 min, PVR values in the
reprostinil group had not yet returned to baseline). The
ncrease in cardiac output was less brisk but more sustained
fter treprostinil inhalation. Systemic arterial pressure
SAP) was unaffected by treprostinil inhalation, whereas a
ransient decrease was observed after iloprost inhalation.
either iloprost nor treprostinil affected gas exchange.
hree-factorial analysis of variance for PVR showed a
ignificant difference between repeated measurements after
nhalation (p[A]  0.0001), no significant difference be-
ween drugs (p[B] 0.1), no difference between treprostinil
igure 2. Response of pulmonary vascular resistance (PVR) and system
ffects. (A) Inhalation of 7.5 g iloprost (in 6 min) versus 7.5 g trepros
6 min) versus 15 g treprostinil (6 min) (n  14, in randomized order)
n  16, in randomized order). Data are shown as percent of baseline
reprostinil.oncentrations (p[C] 0.74), and a significant drug time wnteraction (p[A  B]  0.0001). This translates into a
ignificant effect of both drugs on PVR with comparable
rug potency, but a prolonged drug effect of treprostinil
ompared with iloprost.
In study 1, mild side effects were observed in some
atients with iloprost inhalation at the 7.5-g dose (tran-
ient flush, headache) but were not observed with inhaled
reprostinil at 7.5 or 15 g. Bad taste was reported by most
f the patients after inhalation of treprostinil. This was
ubsequently found to be attributable to the metacresol
reservative contained in the treprostinil solution, which
terial pressure (SAP) to inhalation of treprostinil versus iloprost: dose
6 min) (n  14, in randomized order). (B) Inhalation of 7.5 g iloprost
Inhalation of 7.5 g iloprost (6 min) versus 15 g treprostinil (3 min)
s (mean  95% confidence interval). Circles  iloprost; triangles ic ar
tinil (
. (C)
valueas then left out in study 3.
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Inhaled Treprostinil in Pulmonary Hypertension October 17, 2006:1672–81In study 2, the pharmacodynamics of inhaled placebo or
reprostinil were observed for 180 min. Placebo inhalation
as followed by a gradual increase in PVR over the entire
bservation time. Because of reduced patient numbers in the
20-g treprostinil group (because of side effects, see
elow), the hemodynamic values for this group were not
ncluded in the graphs of this study (Figs. 4 and 5). All
reprostinil doses led to comparable maximal decreases of
VR to 76.5  4.7% (30 g), 73.7  5.8% (60 g), 73.3 
.3% (90 g), and 65.4  4.1% (120 g) of baseline values.
n extended duration of pulmonary vasodilation was noted,
urpassing the 3-h observation period for the 60-g and
0-g (and 120-g) treprostinil doses, whereas in the
0-g dose group the hemodynamic changes had returned
o baseline by the end of this period. Even at the highest
oses, treprostinil had only minor effects on SAP (Fig. 4).
aximal cardiac output was 106.8 3.2% (30 g), 122.9
.3% (60 g), 114.3  4.8% (90 g) and 111.3  3.9%
120 g) of baseline values. The areas between the re-
ponse curves after placebo versus treprostinil inhalation
ere calculated for PVR, PAP, systemic vascular resis-
ance, and SAP (Fig. 5). A nearly maximal effect on PVR
as already observed with 30 g treprostinil, and areas
etween the curves for PVR were not significantly dif-
erent for 30, 60, and 90 g treprostinil. Effects on PAP
igure 3. Hemodynamic response to inhalation of treprostinil versus ilopro
s percent of baseline values (mean  95% confidence interval). Abbreviand SAP were small and did not show a dose-response gelationship. Gas exchange was not affected at doses up to
0 g treprostinil, but arterial oxygen saturation was
ignificantly decreased at a dose of 120 g treprostinil in
ll 3 patients. Further dose increments above 120 g were
ot performed because of this desaturation and a severe
eadache in 1 patient.
Bad taste of the treprostinil aerosol was again reported by
ost patients. Other side effects were flushing (n  1; 30
g), mild transient cough (n  3; 60 g), mild transient
ronchoconstriction that resolved after fenoterol adminis-
ration (n  1; 30 g), and moderate bronchoconstriction
hat resolved after fenoterol administration (n 1; 120 g).
he bad taste, the bronchoconstriction, and the decrease in
aO2 was attributed to metacresol contained in the original
reprostinil solution. With the use of a metacresol-free
olution of treprostinil (University Hospital Giessen, Ger-
any; produced according to the manufacturer’s protocol)
n the subsequent study, these side effects no longer oc-
urred.
Study 3 was performed with metacresol-free treprosti-
il solution, which was tasteless and odorless. A total of
8 patients were enrolled. This study aimed at the
eduction of inhalation time and aerosol volume needed
or pulmonary drug delivery. A modified Optineb (Nebu-
ec, Elsenfeld, Germany) inhalation device was pro-
ata from 44 patients who inhaled both drugs in randomized order, shown
as in Table 1.rammed to produce a constant amount of aerosol during
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October 17, 2006:1672–81 Inhaled Treprostinil in Pulmonary Hypertensionepeatable pulses of aerosol generation. With this device,
reprostinil could be safely administered up to a concen-
ration of 2,000 g/ml without considerable side effects.
here was no relationship between the number or type of
ide effects and treprostinil concentration. Reported side
ffects were mild and consisted of transient cough (n 
), headache (n  2), and jaw pain (n  1).
The reduction of PVR and PAP was comparable among
ll groups (Fig. 6). Treprostinil inhalation reduced PVR to
igure 4. Pharmacodynamics after treprostinil inhalation versus placebo. P
onfidence interval). Maximal decrease of pulmonary vascular resistance (
PVR decrease) seemed to be dose dependent. Abbreviations as in Tab6.3 5.6% (18 pulses, 100 g/ml), 72.9  4.9% (9 pulses, e00 g/ml), 71.2  6.0% (3 pulses, 600 g/ml), 77.4 
.5% (2 pulses, 1,000 g/ml) and 80.3  5.2% (1 pulse,
,000 g/ml). The PAP was reduced to 84.2  4.5% (18
ulses, 100 g/ml), 84.2  4.1% (9 pulses, 200 g/ml),
1.1  4.1% (3 pulses, 600 g/ml), 86  4% (2 pulses,
,000 g/ml), and 88  5.4% (1 pulse, 2,000 g/ml) of
aseline. Cardiac output was moderately increased in all
roups, whereas SAP was not significantly affected.
The ABCs for changes in hemodynamic and gas-
o or treprostinil in doses of 30, 60, or 90 g were inhaled (mean  95%
was comparable for all doses. The duration of pulmonary vasodilationlaceb
PVR)xchange parameters after inhalation of 15 g treprostinil
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Inhaled Treprostinil in Pulmonary Hypertension October 17, 2006:1672–81ersus placebo were calculated for an observation time of
20 min (Fig. 7). The ABCs for both PVR and PAP were
omparable among all groups.
harmacokinetic results from study 2. Peak plasma con-
entrations of treprostinil were achieved 10 to 15 min after
nhalation. Maximal treprostinil plasma concentrations
Cmax) for the 30-, 60-, 90-, and 120-g doses were
.65  0.28 ng/ml (n 4), 1.59 0.17 ng/ml (n 4), 1.74
g/ml (n  1), and 3.51  1.04 ng/ml (n  2), respectively
mean  SEM; Fig. 8).
ISCUSSION
n these studies we asked whether: 1) the acute effects of
nhaled treprostinil would be comparable to or superior to
nhaled iloprost in pulmonary hypertensive patients, 2)
he inhaled prostanoid dose might be increased without
ubstantial local or systemic side effects, and 3) the time of
nhalation, which is 6 to 12 min for iloprost, could be
educed significantly by increasing the concentration of
reprostinil aerosol.
The patient population in these studies included people
igure 5. Areas between the placebo and the treprostinil curves (ABC).
he ABC was calculated for a 3-h period after application of inhaled
reprostinil or placebo from the relative changes of hemodynamic param-
ters (mean  95% confidence interval). Abbreviations as in Table 1.ith different forms of precapillary pulmonary hypertension. tll of these patients had a need for therapy of pulmonary
ypertension, and this reflects the typical population of a
ulmonary hypertension center. There were no major dif-
erences in patient characteristics or baseline hemodynamic
alues among the different groups (Table 1).
In study 1, we showed that the inhalation of treprostinil
nd iloprost in similar doses resulted in a comparable
aximum pulmonary vasodilatory effect. However, marked
ifferences in the response profile were noted. The onset of
he pulmonary vasodilatory effect of inhaled treprostinil was
lower but more sustained compared with that for iloprost,
ith the PVR decrease extending beyond the 1-h observa-
ion period. Although the average dose of treprostinil was
igher than that of iloprost, no systemic effects were noted
fter treprostinil inhalation, whereas flush and transient
AP decrease, accompanied by a more prominent cardiac
utput increase, occurred after iloprost inhalation. These
ide effects were more prominent than in prior studies with
nhaled iloprost, perhaps because the iloprost dose used in
his study was 50% higher than the recommended single
erosolized dose (5 g); additionally, it is possible that the
receding treprostinil inhalation may have added to the
ystemic side effects caused by the iloprost inhalation.
nterestingly, there were no systemic side effects with
reprostinil, although the average effect on PVR was com-
arable to that observed with iloprost.
This study used a crossover design to minimize the effects
f interindividual differences in response to prostanoids.
he short observation period of 1 h was used to avoid an
ncomfortably long catheterization session. A limitation
f this study is that the short observation interval may
ave resulted in a carryover of effects from the first to the
econd period, as suggested by Figure 1. However, we
elieve that this does not alter our conclusions that both
rugs are potent pulmonary vasodilators and that the
ffects of treprostinil are more sustained compared with
hose of iloprost.
The longer duration of action and the virtual absence of
ide effects (except for the bitter taste of treprostinil aerosol,
ubsequently attributed to metacresol) encouraged us to
ncrease the treprostinil dose in study 2 and to extend the
bservation time to 3 h to obtain precise pharmacodynamic
ata. Compared with placebo inhalation, inhaled treprosti-
il, in doses up to 90 g, produced a strong pulmonary
asodilator effect that outlasted the observation time of 3 h.
lthough no pulmonary or systemic vasodilation was ob-
erved after placebo inhalation, there was a gradual increase
n PVR and PAP accompanied by a decrease in cardiac
utput beyond 3 h after treprostinil inhalation. This
nding is consistent with our previous experience from
ong-term catheterization studies, in which PVR tended
o increase gradually after catheter insertion over the
orning hours. This might be attributed to local effects
f the catheter in the pulmonary artery, pain from the
nsertion site, or general discomfort from the investiga-
ion. In study 2, inhalation with metacresol-containing
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October 17, 2006:1672–81 Inhaled Treprostinil in Pulmonary Hypertensionolution might have added to this effect, but this expla-
ation seems very unlikely because of the gradual onset of
he PVR increase.
The long duration of pulmonary vasodilation after a
ingle inhalation of treprostinil may be partially explained by
he stability of this prostanoid. We speculate that trepros-
inil is stored in the lung tissue after inhalation, providing a
low release from the alveolar lining layer or the interstitial
ompartment to the pulmonary vascular smooth muscle
ells. Peak plasma concentrations of treprostinil were ob-
erved 10 to 15 min after inhalation (Fig. 8). This is
onsiderably later compared to inhaled iloprost, with which
eak plasma levels were found immediately after the com-
letion of the inhalation session and plasma half-life was
nly about 8 min (10). This might explain the slower rate of
nset of the pulmonary vasodilator effects and the virtual
bsence of systemic side effects despite the administration of
igher doses of treprostinil. Similar to inhaled iloprost, the
uration of the hemodynamic effect of treprostinil outlasted
he plasma concentrations.
It is also possible that differences in binding characteris-
ics to prostaglandin-E receptors and prostaglandin-I recep-
ors contribute to the different pharmacodynamic profiles of
nhaled treprostinil versus iloprost (11,12). Prostanoids and
igure 6. Hemodynamic responses to the application of 15 g inhaled
oncentration. A pulse of aerosol was generated every 6 s. Treprostinil aero
9 pulses; n  6), 600 g/ml (3 pulses; n  21), 1,000 g/ml (2 pulses; n
ata are shown as mean  95% confidence interval. Abbreviations as inheir analogs selectively bind to their 7 cognate prostanoid Ieceptors, which initiate second messenger signaling that
eads to either vasodilation or vasoconstriction, depending
n the prostanoid receptor specificity of the analog and the
eceptor distribution in the respective vascular bed. Differ-
nces between treprostinil and iloprost in prostanoid recep-
or specificity and activation, together with tissue binding
haracteristics, may explain the improved pulmonary selec-
ivity of inhaled treprostinil.
In study 3, the inhalation time was reduced to literally 1
ingle breath of 2,000 g/ml treprostinil solution, thereby
pplying a dose of 15 g. This drug administration with a
ingle breath induced pulmonary vasodilation for longer
han 3 h compared with placebo inhalation. Side effects
ere minor, of low frequency, and not related to drug
oncentration. It was an unanticipated and most encour-
ging finding that such high concentrations of treprosti-
il were well tolerated. However, training of the patients
or effective administration of such powerful inhaled
rugs by a single breath will be of great importance in
uture studies.
The pharmacokinetic studies (Fig. 8) showed that Cmax
or the 60-g (1.59-ng/ml) and 90-g (1.74-ng/ml) doses
ere in accordance with previously reported plasma concen-
rations of subcutaneous or intravenous treprostinil delivery.
rostinil. The inhalation time was minimized by increasing treprostinil
as inhaled in concentrations of 100 g/ml (18 pulses; n  6), 200 g/ml
, and 2,000 g/ml (1 pulse; n  8). Placebo data correspond to Figure 4.
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Inhaled Treprostinil in Pulmonary Hypertension October 17, 2006:1672–81dministration of treprostinil at a rate of 15 ng/kg/min over
50 min in healthy volunteers led to a Cmax of 1.47  0.2
g/ml and 1.57  0.31 ng/ml, respectively (13). Subcuta-
eous infusion over 28 days in healthy volunteers at a rate of
5 ng/kg/min led to a Cmax of 1.56  0.24 ng/ml (9).
ubcutaneous infusion rates of 10 to 20 ng/kg/min are
linically efficacious in pulmonary arterial hypertension pa-
igure 7. Areas between the placebo curve and the responses to 15 g tre
etails of aerosol generation, see Figure 5. Mean  SEM of relative chan
n Table 1.ients (14). In the patient who reported severe headache tfter inhaling 120 g treprostinil, a Cmax of 4.57 ng/ml was
easured. This suggests that the systemic plasma concen-
ration might determine the systemic side effect profile,
hile local lung tissue concentrations determine the pulmo-
ary vasodilator effect.
We conclude that inhaled treprostinil exerts high pulmo-
ary selectivity and leads to sustained pulmonary vasodila-
inil applied at increasing concentrations to minimize inhalation time. For
hemodynamic parameters (observation time, 120 min). Abbreviations asprost
ges ofion. Concentration increases by more than 2 orders of
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October 17, 2006:1672–81 Inhaled Treprostinil in Pulmonary Hypertensionagnitude (bringing down inhalation time to a single
reath), and dose increases by more than 1 order of
agnitude, were effective and well tolerated. These findings
uggest that inhalation of treprostinil may offer a new strategy
or the treatment of pulmonary arterial hypertension.
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